OMERS ADMINISTRATION Corp Purchases 48,000 Shares of Cellebrite DI Ltd. $CLBT

Posted by Brenda Bartman on Jul 30th, 2026

OMERS ADMINISTRATION Corp grew its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 85.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,166 shares of the company’s stock after purchasing an additional 48,000 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Cellebrite DI were worth $1,435,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its position in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI during the third quarter worth approximately $40,000. CWM LLC raised its holdings in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares during the last quarter. First Horizon Corp raised its position in Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after buying an additional 2,337 shares during the last quarter. Finally, Vestcor Inc bought a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $70,000. 45.88% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cellebrite DI

In other news, CEO Thomas E. Hogan sold 103,188 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer owned 590,777 shares in the company, valued at $9,310,645.52. This trade represents a 14.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive owned 440,101 shares in the company, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 158,191 shares of company stock valued at $2,479,438. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CLBT has been the subject of several recent research reports. DA Davidson assumed coverage on Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price objective for the company. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Finally, Needham & Company LLC decreased their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

View Our Latest Report on CLBT

Cellebrite DI Trading Up 1.5%

NASDAQ:CLBT opened at $15.07 on Thursday. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98. The company has a 50-day moving average price of $14.27 and a 200-day moving average price of $14.20. The stock has a market cap of $3.76 billion, a price-to-earnings ratio of 53.82, a P/E/G ratio of 1.84 and a beta of 1.17.

About Cellebrite DI

(Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.